Marc Sluijs

Clipperton is a leading investment bank advising high-growth innovative businesses and their shareholders on their strategic transactions. We focus exclusively on digital and technology-driven sectors, and have forged personal

relationships with decision-makers amongst top tier global corporates and investors worldwide. Since 2003 (and even the late '90s for our founding team), we pride ourselves on assisting leading innovators in the long run in their strategic and financial development. We have realized over 400 transactions in the broader technology industry, assisting tech champions in complex cross-border M&A, growth financings and sophisticated leveraged buyouts. Clipperton has extensive experience in digital health, working with leading companies such as Withings, Tilak, Kinvent, Gymlib, Dental Monitoring and more.

> Currently advising on several digital health investment and M&A opportunities (both buy and sell side) - contact me for information.

Advising key stakeholders in global digital health ecosystem on digital health investment & M&A. Global advisory assignments (APAC, MENA, US, EU) with (1) large investors (growth VC, PE), (2) Life Sciences Companies, Insurers, CROs, (3) Digital Health companies. Selected areas of experience (non exhaustive): Digital Therapeutics (DTx), RPM, Chronic disease management (diabetes, hypertension, cancer, COPD, MSK), Surgery Intelligence, Telehealth, AI enabled Drug Discovery and Development, ePRO, eCOA, RBM, Virtual/Remote trials

Mubadala Investment Company actively manages a worldwide portfolio supporting the vision of a globally integrated and diversified economy, through sustainable returns to its shareholder, the Government of Abu Dhabi. In March 2018, Abu Dhabi Investment Council (ADIC) joined the Group. Mubadala's US $229 billion portfolio spans five continents with interests in aerospace, ICT, semiconductors, metals and mining, renewable energy, oil and gas, petrochemicals, utilities, healthcare, real estate, pharmaceuticals and medical technology, agribusiness and a global portfolio of financial holdings.

Our pharmaceutical and medical technology investments have a low correlation with Mubadala's wider portfolio and our current priority sub-sectors include:

• Pharmaceuticals, with a focus on the rapidly-growing biologics and complex small molecules segments

• Medical Technology, with a focus on orthopedic, cardiovascular, chronic care, and home health solutions

• Healthcare IT and Digital Health, given the growing trends of digitization, remote care, and big data & analytics within healthcare

• Animal Health, whose sustained growth levels are driven by rising pet adoption and the importance of pet care to many global households, as well as continued protein consumption globally